The earnings call presented a generally positive outlook with significant achievements, including revenue growth, cost management, and strategic advancements like the VAN approval and NOPAIN Act inclusion. However, challenges remain with specific product revenue declines and financial write-offs.

Company Guidance

During Heron Therapeutics' Q3 2024 earnings call, the company provided updated guidance and highlighted several key metrics. Heron narrowed its Q4 2024 net revenue guidance to a range of $37 million to $43 million, reflecting early success in that quarter. The company reported total acute care net revenues of $7.4 million, with ZYNRELEF contributing $6.3 million and APONVIE $1.1 million. In the oncology sector, CINVANTI generated $22.6 million and SUSTOL $2.8 million in net revenues for the quarter. Heron also improved its gross margin significantly, increasing from 41% to just over 72%, and doubled its gross profit to $75 million over the past nine months. The company reported a net loss of $4.8 million for Q3 2024, compared to $25 million in Q3 2023, and a year-to-date cash burn of less than $10 million. Adjusted EBITDA guidance was revised to a positive range of $2 million to $5 million. Heron continues to focus on financial efficiency while driving revenue growth, with significant developments anticipated from the launch of the Vial Access Needle (VAN) and the implementation of the NOPAIN Act in 2025.

Financial Performance Improvement

Revenues grew over 12% in the past 9 months, with gross margin improving from 41% to over 72%. Gross profit doubled from $37 million to $75 million.

FDA Approval of Vial Access Needle

The Vial Access Needle (VAN) was approved on September 24, reducing drug preparation time significantly and is expected to launch by the first week of December.

Inclusion in NOPAIN Act

ZYNRELEF was included in the final version of the NOPAIN Act, which supports non-opioid alternatives, effective January 2025, providing a potential tailwind for sales.

CrossLink Partnership Success

The CrossLink partnership added 21 new ordering accounts per month, generating nearly 40,000 ZYNRELEF units and approximately $4.4 million in net revenue.

Cost Efficiency Achievements

SG&A expenses decreased significantly, and the company reported a substantial turnaround with adjusted EBITDA projected to be positive, between $2 million and $5 million.

---

Heron Therapeutics (HRTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

HRTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 20, 2025	2024 (Q4)	-0.03 / -	-0.07	―	―	―
Nov 12, 2024	2024 (Q3)	-0.04 / -0.03	-0.17	82.35% (+0.14)
Aug 06, 2024	2024 (Q2)	-0.04 / -0.06	-0.35	82.86% (+0.29)
May 07, 2024	2024 (Q1)	-0.07 / -0.02	-0.27	92.59% (+0.25)
Mar 12, 2024	2023 (Q4)	-0.15 / -0.07	-0.17	58.82% (+0.10)
Nov 14, 2023	2023 (Q3)	-0.29 / -0.17	-0.38	55.26% (+0.21)
Aug 14, 2023	2023 (Q2)	-0.22 / -0.35	-0.55	36.36% (+0.20)
May 11, 2023	2023 (Q1)	-0.22 / -0.27	-0.63	57.14% (+0.36)	―
Mar 23, 2023	2022 (Q4)	-0.32 / -0.17	-0.54	68.52% (+0.37)
Nov 08, 2022	2022 (Q3)	-0.38 / -0.38	-0.51	25.49% (+0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

HRTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 12, 2024	$1.84	$1.28	-30.43%
Aug 06, 2024	$2.67	$2.00	-25.09%
May 07, 2024	$2.84	$2.87	+1.06%
Mar 12, 2024	$2.36	$3.01	+27.54%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---